Although mouse models may not entirely predict clinical outcomes, we believe that this study provides a solid foundation for further investigation of CSTA as an immunomodulator of innate and adaptive immune responses in humans and that CSTA is thus a valid candidate for activation immunotherapy in patients with pancreatic cancer. Here, CSTA is linked to familial pancreatic carcinoma.